9月30日，海南海药（维权）盘中上涨2.03%，截至09:51，报5.53元/股，成交2666.97万元，换手率 0.42%，总市值71.74亿元。 资金流向方面，主力资金净流入285.67万元，特大单买入115.59万元，占比4.33%，卖出0.00元，占比 0.00%；大单买入622.79万元，占比23.35%，卖出452.71万元，占比16.97%。 海南海药今年以来股价涨15.45%，近5个交易日跌0.72%，近20日跌6.43%，近60日跌9.93%。 今年以来海南海药已经3次登上龙虎榜，最近一次登上龙虎榜为6月3日。 资料显示，海南海药股份有限公司位于海南省海口市秀英区南海大道192号，成立日期1992年12月30 日，上市日期1994年5月25日，公司主营业务涉及中西成药、精细化工产品、化学原料药、保健品及与 医药工业相配套的进出口贸易。主营业务收入构成为：其他品种29.93%，肠胃康25.07%，医疗服务 18.60%，原料药及中间体13.27%，头孢制剂系列10.19%，其他(补充)2.95%。 分红方面，海南海药A股上市后累计派现4.66亿元。近三年，累计派现0.00元。 机构持仓方面，截 ...

一纸流拍公告，将海南海药（维权）（000566）推至风口浪尖。9月22日至23日，公司第二大股东南方 同正所持1.24亿股（占总股本9.54%）在京东司法拍卖平台公开拍卖，却因无人出价而流拍。此次起拍 价定为5.682元/股，若成交可回笼资金超7亿元，但市场用"沉默"表达了对其基本面的担忧。 国资入主后，公司虽推动"两非两资"处置、减负降本，2024年通过资产转让回笼资金6155.77万元，并 实现部分诉讼回款，但经营基本面未获根本改善。2017年至2024年，公司扣非净利润连续八年为负， 2024年归母净亏损高达15.25亿元。 财务危机加剧：净资产骤降、退市风险临门 2025年中报显示，海南海药营收4.5亿元，同比下滑24.12%；归母净亏损1.58亿元，虽较去年同期收 窄，但主要依赖销售费用压缩，而非业务造血能力提升。 流拍背后：市场信心缺失与股价倒挂 流拍并非无迹可寻。在拍卖关键期（9月19日至23日），海南海药股价连续下跌，收盘价从5.88元跌至 5.57元，最终低于起拍价。流拍折射出投资者对海南海药治理遗留问题、持续亏损及高负债的深度忧 虑。 南方同正作为公司重要股东，其持股已全部处于质押和冻结状 ...

证券日报网讯海南海药（000566）9月25日在互动平台回答投资者提问时表示，截至2025年9月20日，公 司股东户数为74，927户。 ...

图片由AI生成 一纸流拍公告，让海南海药（000566）这家创立于1965年的老牌药企坐上无人问津的"冷板凳"。 海南海药9月23日公告，公司第二大股东南方同正所持已质押的1.24亿股股票，于9月22日~23日在京东司法拍卖平台进行拍卖，但因无人出价，拍卖未能成 功。拍卖股份占南方同正所持股份的92.86%，占总股本的9.54%。 一次本该"清仓式"易主的拍卖，却连一次应价都没等到。究其根本，或许源于市场对海南海药基本面以及前实控人刘悉承时期遗留的治理沉疴的担忧。 | | | 近期A股上市公司司法拍卖情况 | | | --- | --- | --- | --- | | 上市公司 | 拍卖截止日期 | 拍卖股份占总股本比例 | 拍卖结果 | | 海南海药 (000566) | 9月23日 | 9.54%(1.24亿股) | 流拍 | | 杉杉股份 (600884) | 9月21日 | 约0.19% (426万股) | 以5771万元成功拍出 | | 启迪环境 (000826) | 7月18日 | 约0.14% (200万股) | 以363. 2万元成功拍出 | | 尚纬股份(603333) | 4月14日 | ...

海南海药股份有限公司 关于持股 5%以上股东部分股份被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000566 证券简称：海南海药 公告编号：2025-058 特别提示 1、本次司法拍卖标的为公司持股 5%以上股东深圳市南方同正投资有限公司 （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。 2、根据京东司法拍卖平台页面显示的拍卖结果，本次股份拍卖因在规定时 间内无人出价未能竞拍成功。 公司于 2025 年 8 月 23 日披露了《关于持股 5%以上股东部分股份被司法拍 卖的提示性公告》（公告编号：2025-051），湖北省武汉市中级人民法院（以下 简称"武汉中院"）于 2025 年 9 月 22 日 10 时至 2025 年 9 月 23 日 10 时 止在京东网（http://sifa.jd.com/2251）进行公开司法拍卖南方同正所持海南 海药已质押的 123,825,900 ...

Group 1 - The company Hainan Haiyao reported that as of September 10, 2025, the number of shareholders is 76,345 [2]

Group 1 - The pharmaceutical industry in China is undergoing significant changes, with a shift from a focus on prevention to innovation, driven by the "Three Medical Linkage" policy and new healthcare reforms [1] - Hainan Haiyao is adapting to the complex industry landscape by leveraging state-owned enterprise reform and scientific innovation to enhance its R&D capabilities for sustainable high-quality development [1] Group 2 - Hainan Haiyao has established a "1234" development strategy focusing on high-quality growth, emphasizing three major missions: "defense, emergency, and public welfare," while expanding its chemical drug sector and high-end medical device platform [2] - The company aims to become a leading manufacturer of anti-infection drugs in China and a globally influential high-end medical device manufacturer, with aspirations to be the largest producer of raw materials and intermediates in China [2] Group 3 - Hainan Haiyao has defined a comprehensive product pipeline with a "6523 product mix," including 6 types of formulations, 5 types of raw materials, 2 types of intermediates, and 3 types of traditional Chinese medicine products [3] - Since 2023, the company has initiated 22 product projects across various dosage forms, including sustained-release, oral solutions, capsules, and effervescent tablets, targeting conditions such as hyperlipidemia, epilepsy, and infections [3] - The company has successfully passed consistency evaluations for 18 products, including minocycline hydrochloride capsules, which is the first in China to achieve this, creating new profit growth points for future development [3] - Hainan Haiyao is enhancing technical innovation through collaborations with research institutions and universities, establishing joint laboratories to expedite the discovery and development of new drug candidates [3]

Group 1 - The company conducted an investor relations activity focusing on the progress of innovative drug research and development, overseas rights cooperation, resolution of industry competition, and layout in the health sector [2] - The company is currently conducting Phase IIa clinical trials for the innovative drug Painegabine, with 100% enrollment of the target 36 participants, and expects to unblind and read results by the end of 2025 [2] - The company has completed the Phase II clinical trial for Fluofenone and is preparing for Phase III clinical trials, with data expected to be read out by the end of this year [2] Group 2 - The company is actively seeking suitable partners for overseas rights cooperation for Painegabine [2] - The company is addressing industry competition commitments with a focus on resolution [2] - The company has partnered with AFT Pharmaceuticals from New Zealand to become the exclusive sales agent for five products and signed a strategic cooperation agreement with Malaysia's Aikang International Group to leverage the Hainan Free Trade Port policy [2] Group 3 - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection of Paliperidone for schizophrenia treatment, and aims to develop a product cluster [2] - The company is enhancing its product pipeline in traditional Chinese medicine, focusing on gastrointestinal health products, and aims to expand overseas registration and sales [2] - The company is deepening collaborations with universities and research institutions to explore high-end formulations and international partnerships [2]

Group 1 - The core viewpoint of the article is that Hainan Haiyao (SZ 000566) has conducted an investor survey, providing insights into its business structure and financial performance [1] - As of the first half of 2025, Hainan Haiyao's revenue composition is as follows: 78.45% from pharmaceuticals, 18.6% from medical service fees, and 2.95% from other businesses [1] - The current market capitalization of Hainan Haiyao is 7.7 billion yuan [1]

Clinical Trials and Drug Development - The company is conducting Phase IIa clinical trials for the drug Paenagabin, with a target enrollment of 36 cases, which has been fully achieved at a 100% completion rate. Preliminary data shows promising therapeutic effects [2][3] - The Phase II data for Paenagabin is expected to be unblinded and results read out by the end of 2025 [2][3] - The Phase II clinical research for another drug, Fluorofenone, has completed subject enrollment and data cleaning, with results expected to be revealed by the end of this year [3][4] - Preparations for the Phase III clinical trials of Fluorofenone are underway, anticipated to start between the end of this year and early next year [3][4] Market Expansion and Partnerships - The company is actively seeking international partners for the commercialization of innovative drugs, with future expansion dependent on the Phase II clinical results of Paenagabin [3][4] - A strategic cooperation agreement has been signed with Malaysia's Aikang International Group to introduce high-quality health products and promote traditional Chinese medicine products in the Malaysian market [3][4] Product Development and Focus Areas - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection for the treatment of schizophrenia, thereby forming a product cluster in this area [4] - The company aims to expand its gastrointestinal product line, particularly the Gut Health series, targeting grassroots medical institutions and increasing user base [4] - There is a commitment to deepen collaborations with universities and research institutions to enhance competitiveness in high-end formulations [4] Risk Management - There are uncertainties regarding the success of subsequent clinical trials for innovative drugs and the potential for obtaining approval from the National Medical Products Administration [4] - The company emphasizes the importance of timely information disclosure regarding the progress of innovative drugs and encourages investors to make cautious decisions [4]